Home › Trial NCT06133556
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
- Trial IDNCT06133556
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorInstitute of Hematology & Blood Diseases Hospital, China
- Enrollment237
- Start date2023-11-24
- ConditionsAcute Myeloid Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.